The UK interstitial lung disease long COVID-19 study

The UK Interstitial Lung Disease Long-COVID19 study (UKILD-Long COVID): understanding the burden of interstitial lung disease in long COVID

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN16650532

Enrollment

2000

Registered

2021-12-08

Start date

2021-08-18

Completion date

Unknown

Last updated

2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19 (SARS-CoV-2 infection) Infections and Infestations

Interventions

Participants will be required to attend up to three clinic visits over a 12-month period: at three months post initial COVID infection, 6 months and 12 months. Recruitment 1. Participants who have be

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Aged 18 to 99 years old 2. Evidence of SARS-CoV-2 infection confirmed by PCR or serology 3 months (+/- 6 weeks) earlier 3. Clinical indication for a chest CT scan as per clinician judgment 4. Participants who have been identified and consented for the main PHOS-PCOVID study are also eligible to join this study 5. Allow inclusion of patients who are receiving up to 10 mg of prednisolone a day

Exclusion criteria

Exclusion criteria: 1. Life-limiting illness within 12 months 2. Significant pre-existing lung disease prior to March 2020, which in the investigator’s judgement could make the chest CT scans difficult to interpret

Design outcomes

Secondary

Measure	Time frame
1. Lung function decline =10% OR worsening extent of ILD on CT scan using image analysis or MDT discussion at 3 and 12 months (+/- 3 months) after acute infection 2. Resolution of ILD: any of the following: =10% relative improvement in FVC, DLco, or reduction of radiological extent at 12 months (+/- 3 months) post SARS-CoV-2 3. Persistence of ILD in those not meeting the definition of progression or resolution at 12 months (+/- 3 months) post SARS-CoV-2 4. Persistence of ILAs measured using Computerised Tomography at 12 months (+/- 3 months) post SARS-CoV-2 5. Markers of severity of acute infection (e.g. CRP) measured using initial clinical assessment at 12 months (+/- 3 months) post SARS-CoV-2 6. Medical therapy used for acute infection measured using clinical records at 12 months (+/- 3 months) post SARS-CoV-2 7. Breathlessness measured using the Medical Research Council dyspnoea scale, Dyspnoea 12 at 3 months, 6 months (+/- 6 weeks) and 12 months (+/- 3 months) post SARS-CoV-2 infection 8. Fatigue measured using FACIT-F at 3 months, 6 months (+/- 6 weeks) and 12 months (+/- 3 months) post SARS-CoV-2 infection 9. Cognition measured using the Montreal Cognition Assessment (MOCA) at 3 months, 6 months (+/- 6 weeks) and 12 months (+/- 3 months) post SARS-CoV-2 infection 10. Quality of life measured using Short Form-36 (SF-36), EQ5D-5L at 3 months, 6 months (+/- 6 weeks) and 12 months (+/- 3 months) post SARS-CoV-2 infection 11. Impact of COVID19 on aerobic capacity and endurance measured using the incremental shuttle walk test or cardiopulmonary exercise test, if clinically indicated, at 3 months, 6 months (+/- 6 weeks) and 12 months (+/- 3 months) post SARS-CoV-2 infection Exploratory: 1. Exploratory circulating biomarkers measured using whole blood RNA sequencing (including peripheral blood mononuclear cells) and analysis of epigenetic modifications and proteomics at 3 months, 6 months (+/- 6 weeks) and 12 months (+/- 3 months) post SARS-CoV-2 infection 2. Se	—

Measure

Time frame

1. Lung function decline =10% OR worsening extent of ILD on CT scan using image analysis or MDT discussion at 3 and 12 months (+/- 3 months) after acute infection 2. Resolution of ILD: any of the following: =10% relative improvement in FVC, DLco, or reduction of radiological extent at 12 months (+/- 3 months) post SARS-CoV-2 3. Persistence of ILD in those not meeting the definition of progression or resolution at 12 months (+/- 3 months) post SARS-CoV-2 4. Persistence of ILAs measured using Computerised Tomography at 12 months (+/- 3 months) post SARS-CoV-2 5. Markers of severity of acute infection (e.g. CRP) measured using initial clinical assessment at 12 months (+/- 3 months) post SARS-CoV-2 6. Medical therapy used for acute infection measured using clinical records at 12 months (+/- 3 months) post SARS-CoV-2 7. Breathlessness measured using the Medical Research Council dyspnoea scale, Dyspnoea 12 at 3 months, 6 months (+/- 6 weeks) and 12 months (+/- 3 months) post SARS-CoV-2 infection 8. Fatigue measured using FACIT-F at 3 months, 6 months (+/- 6 weeks) and 12 months (+/- 3 months) post SARS-CoV-2 infection 9. Cognition measured using the Montreal Cognition Assessment (MOCA) at 3 months, 6 months (+/- 6 weeks) and 12 months (+/- 3 months) post SARS-CoV-2 infection 10. Quality of life measured using Short Form-36 (SF-36), EQ5D-5L at 3 months, 6 months (+/- 6 weeks) and 12 months (+/- 3 months) post SARS-CoV-2 infection 11. Impact of COVID19 on aerobic capacity and endurance measured using the incremental shuttle walk test or cardiopulmonary exercise test, if clinically indicated, at 3 months, 6 months (+/- 6 weeks) and 12 months (+/- 3 months) post SARS-CoV-2 infection Exploratory: 1. Exploratory circulating biomarkers measured using whole blood RNA sequencing (including peripheral blood mononuclear cells) and analysis of epigenetic modifications and proteomics at 3 months, 6 months (+/- 6 weeks) and 12 months (+/- 3 months) post SARS-CoV-2 infection 2. Se

—

Primary

Measure	Time frame
Multi-disciplinary team (MDT) confirmed diagnosis of ILD at 12 months (+/- 3 months) after acute infection	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026